Harshad Amin is an Oncology physician affiliated with Boca Raton Regional Hospital. OpenAlex indexes 65 publications with 876 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8200 W Sunrise Blvd Bldg C
Plantation, FL 333225426
Telephone
954-370-8585Registry record last updated 23 Apr 2019.
Industry payments
85 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202523 payments
- PFIZER INC.Program year202541 payments
- Merck Sharp & Dohme LLCProgram year202515 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
56.5%Erythropoiesis-stimulating Agent49.6%Darbepoetin alfa100%Part B, office-administered≥40 patientsIron, parenteral preparations6.4%Ferric derisomaltose100%Part B, office-administered≥30 patients+ 2 more classes in this area
Cancer & immunology
28.3%PD-1 inhibitor26.6%Pembrolizumab100%Keytruda0%Part D + Part B<11 patientsAromatase Inhibitor0.6%Letrozole71%Anastrozole26%Exemestane3%Part D<11 patients+ 13 more classes in this area
Musculoskeletal
9.4%RANK Ligand Inhibitor9.4%Denosumab100%Part B, office-administered≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.
Journal of Clinical Oncology
2025 - DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
Journal of Clinical Oncology
2025 - Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
British Journal of Haematology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Seth Baum, MD
Boca Raton Regional Hospital
Alexander Kulik, MD, MPH
Boca Raton Regional Hospital
Brian Snelling, MD
Boca Raton Regional Hospital
Ivanka Kovalyshyn, DO
Boca Raton Regional Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”